Cannassure Therapeutics Investors Deck

Cannassure Therapeutics Ltd
Investors Deck | February 2019
TASE:

© Cannassure Therapeutics Ltd
2
© Cannassure Therapeutics LtdWe do it right
This presentation has been prepared by the
Company and should not be considered as
a recommendation or recommendation for
the purchase or sale of securities and / or
investment in Cannassure Therapeutics
Ltd. This presentation is intended for the
purpose of providing information only. The
Company is not responsible and shall not be
considered liable for any damage and / or
loss that may be caused as a result of any
information contained in this presentation
and the use of this information.
In addition, this presentation may include
forward-looking information, as defined
in the Israeli Securities Law, 1968. Such
information includes, forecasts, estimates,
estimates based on other information
relating to future events and / or matters,
the realization of which is uncertain and is
not under the Company's control ("forward-
looking information."). Forward-looking
information is not a proven fact and is based
on subjective assumptions, estimates and
forecasts made by the Company at that time
only. The realization or non-realization of
the forward- looking information may be
affected from risk factors that characterize
the company's operations, as well as from
developments in the competitive and
business environment and from external
factors that influence the Company's
operations, which cannot be foreseen and
which are not controlled by the Company.
Forward-looking information is not accurate,
and the Company is unable to assess it in
advance, as most of this information is not
under its control. Therefore, this information,
in whole or in part, may change substantially
at any time as a result of the influence of
various factors, including but not limited
to changes in market conditions and / or
competition in the market and / or in the
business environment. The results and
achievements of the Company in the future
may be materially different than those
presented in the presentation. In addition,
forward-looking forecasts and evaluations
are based to update evaluations so they
would reflect events and/or circumstances
that could appear after preparing this
presentation.
2
Forward
Looking
Statements

3
Our
Mission
Cannassure's vision is to become a leading, world-class, trusted developer
and provider of top-quality medical grade cannabis products as well as
pharmaceutical cannabinoid medicines, addressing a broad range
of unmet medical needs.
Our
Vision
© Cannassure Therapeutics LtdWe do it right
Cannassure will develop and commercialize a wide range of effective,
high standard and affordable medical cannabis products as well as
pharmaceutical cannabinoid medicines, to enhance treatment and
improve people's quality of life worldwide.
This will be accomplished by facilitating a holistic integrated production
system including an advanced agritech breeding and cultivation indoor
facility, a state-of-the-art extraction and processing facility, together
with scientifically advanced R&D.
Cannassure is committed to quality, excellence, innovation and integrity.

4
4
Our Company
Cannassure (TASE symbol: CSURE) is launching a holistic and integrated medical cannabis
value chain operation. Activity includes breeding, cultivation, extraction, R&D and
distribution of medical cannabis products
The company was founded by Solbar Food Technologies (~ 69.5%), a leading food manufacturer
in Israel, with the intention of instilling its applied 60 years of industrial expertise and know-how
Shareholder’s equity includes ~ 51.2 Million outstanding shares and approx. 9.6 Million
tradable stock options, divided into three series, with strike price of 2-3 ILS
We do it right

5
5
We do it right
Major Activities So Far
In the process of extracting and processing, cannabis
oil for the purpose of developing production procedures
in the company's certified lab
In the process of constructing an advanced, agritech
indoor growing facility for cultivating uniform and
consistent flowers, based on superior breeding strains
Signed distribution agreement with Hadassah Medical
for marketing collaboration
In the process of constructing a cutting edge extraction
and processing facility
Established a highly experienced management team,
skilled in international business, bio-tech and food
manufacturing
Received initial permits from the Israeli Medical
Cannabis Authority (IMCA) for breeding, cultivating,
processing, research and development (R&D)
and storage of cannabis
Initiated preliminary development plan for unique
pharmaceutical cannabis products
Granted financial support by the Israel Innovation
Authority for the development of innovative
cannabis extraction methods
Signed binding MOU with Cannika Holdings, to
establish an agritech incubator specializing in
cannabis innovation, located within the
company's campus

6
6
The group invested 17.5M ILS in Cannassure
A 60-year-old leading company of high quality
botanical extractions
Customers over the years included global leading food
and pharmaceutical companies, such as Unilever,
Nestlé, Novartis, Janssen, Merck & GSK
Operates in accordance with quality standards
Annual income of 500M ILS
Cannassure is based on the
know-how and experience of
Solbar, including the extraction
and processing of botanical
extracts in a controlled
environment and manufacturing
in large industrial scale
Solbar provided Cannassure
with labs and facilities spanning
over 5,500 sqm
We do it right
Solbar Food Technologies Group

7
Former commander of the Israel Air Force and Head
of the IDF Planning Directorate, Mr. Nechushtan brings
extensive managerial experience, including formulating
strategy, creating work plans and leading processes.
These he performed in the Air Force, the IDF and the
private sector, in the fields of technology and cyber. He
holds a B.Sc. cum laude in Mathematics and Computer
Science from the Hebrew University of Jerusalem,
an MBA from Northwestern University and Tel Aviv
University, and an Advanced Management Program
(AMP) from Harvard University.
Having over 15 years of extensive international
experience in operations management and management
consulting, Mr. Amir has served 8 years in an executive
position at The Bread Factory, a top of the range UK
based food manufacturer, and 5 years as Solbar’s CEO.
Mr. Amir holds a B.Sc in Industrial Engineering and
Management and M.Sc in International Business from
Birkbeck, University of London.
Bringing extensive experience in drug delivery
systems and drug device combination; holding
a Ph.D in Medical Science (neurobiology) from
the Hadassah Medical School and a postdoctoral
training in neurobiology from Haifa University,
where she was appointed for a postdoctoral
fellowship, Eshkol Laurate, 2012 – 2014 on novel
approaches for Alzheimer Disease therapy. Her
field of expertise is neurodegenerative disorders.
A seasoned entrepreneur with extensive
knowledge in business development and company
transformation. A former executive at Bluephoenix
Solutions (NASDAQ: MDSY) and Alcobra Pharma
(NASDAQ: ADHD), Mr. Peles holds a BA in
Economics and Accountancy from the Hebrew
University of Jerusalem and an MBA and MA (Law)
degree from Tel Aviv and Bar Ilan Universities.
Major General Ido Nehushtan
Chairman of the Board
Ran Amir
CEO and BOD Member
Dr. Hadile Ounallah-Saad
VP R&D
Nir Peles, CPA, MBA, MA(LAW)
Founder, BOD Member
& VP Business Development
We do it right
Executive Team

8
Bringing 30 years of experience in leading and managing
international biomed and hi-tech companies from start-up
to market penetration and sales, including business and
clinical strategy, raising finance, technological development,
establishing marketing and sales systems. Over the
years, Steven has managed publicly traded companies
including Exalenz Bioscience (TASE: EXEN) and Micromedic
Technologies (TASE: MCTC).
Dr. Less is a multi-disciplinary, R&D professional
with unique expertise in Life Sciences, Genetics, and
Bioinformatics. He has over a decade of experience
leading R&D and operational business units for several
international companies, including Syngenta (NASDAQ:
SYENF) and Compugen (NASDAQ: CGEN). Dr. Less holds a
Ph.D from the Weizmann Institute of Sciences, Department
of Plant Science; an M.Sc in physiology and immunology
from the Israel Institute of Technology’s Faculty of Medicine;
and a B.Sc in Animal Science from the Hebrew University of
Jerusalem, Faculty of Agriculture.
With 13 years of experience in various finance
positions, Mr. Neufeld has served three years
as the CFO of Solbar Food Technologies.
Previously, Mr. Neufeld held positions at CHS
Inc (NASDAQ: CHSCP). U.S. headquarters
working for their Processing and Food
Ingredients Division and at PWC Israel. Mr.
Neufeld earned his Bachelor's Degree in
Accounting and Economics from the Ben-
Gurion University of the Negev.
With 15 years of extensive, international experience
in Quality Management and R&D, Dana has
previously served in senior management positions
in companies such as GreenMarket, China
and provided consulting services for the food
manufacturing sector. Mrs. Marom holds a B.Sc
in Biochemistry and Food Technology from the
Hebrew University of Jerusalem and an EMBA from
the College of Management Academic Studies.
Steven Eitan
VP Strategy
Dr. Hadar Less
Agri-Consultant
Adi Neufeld
CFO
Dana Marom
Chief Quality Manager
We do it right
Executive Team

9
$28B 2024
)MarketWatch, September 2018(
Global cannabis market forecast growth
by
Major trends in the medical cannabis
global market:
Widespread recognition of the virtues and
effectiveness of medical cannabis products
Significant increase in demand for medical
cannabis treatments for dozens of medical
indications
Increased investments for research and
development of medical cannabis products
Increasing number of countries that
authorized the use and trade of medical
cannabis products
Regulatory requirements reform for the use of
medical cannabis products
Price reductions of raw cannabis yields,
highlights the major business opportunity
in the development and top-quality
extraction of innovative medical cannabis
products
We do it right
Medical Cannabis-
Opportunity and Global
Market Trends

10
Cronos Inc CRON
Canopy Growth WEED.TO
Aurora ACB.TO
GW GWPH
Tilray TLRY
Aphria APHA
Market Cap
Feb 1st
, 2019
Billions US dollars
Trailing 12 months
Revenues
Millions US dollars
SymbolCompany
We do it right
Leading Cannabis Companies
$3.7B
$16.8B
$7.4B
$4.5B
$7.7B
$2.4B
$9M
$73M
$60M
$13M
$33M
$47M

11
Development of unique medical products
Patent protected, molecular based and cannabis specific for
medical indications in large and growing global markets.
Establishing a technological incubator for medical cannabis
innovation, within the Cannassure campus, together with
Cannika Holdings
R&D
Breeding
Development of unique cannabis strains
Creating value for the medical cannabis and
pharmaceutical industries, using advanced breeding
technology
Cultivation
Building an indoor growing facility
Cultivation in a controlled environment, enabling quality
consistent yields in accordance with (IMC - GAP) standards
in 4000 sqm facility
Processing
Extraction and processing of premium quality cannabis oil
Large scale production of premium quailty cannabis oil,
cannabinoid distillation and APIs, complying with Israeli
Accreditation IMC - GMP, preparing for EU - GMP accreditation
Distribution
Distribution
An agreement with Hadassah Medical for distribution to
pharmaceutical companies, pharmacy outlets and licensed
customers, in accordance with (IMC - GDP). Exploring additional
opportunities with international affiliations
We do it right
Cannassure is
Establishing a
Comprehensive Value
Chain, Including All
Stages of Medical
Cannabis Production

12
Cannassure is building its indoor
growing facility in accordance with
IMC - GAP agricultural standards
Indoor cultivation enables quality and consistent products and has significant advantages including:
Increase of annual growth
cycles (approximately 6
cycles compared to 2-3
cycles in outdoor)
No exposure to
weather conditions
Higher efficiency by savings
in water and grow area
Cutlivation without
herbicides and pesticides
~ 20 tons potential
annual capacity of
cannabis flowers
The facility is being built in an existing industrial
building within the Solbar compound and will benefit
from reduced-cost electricity, natural gas supply,
reverse osmosis water supply and sewage treatment
in accordance with environmental regulation
The Cannassure Agronomy
Team brings decades of
experience of leading global
agritech companies
We do it right
Indoor Growing Facility

13
1
2
3
Current extraction and processing
activities in the company's lab:
Cannassure is in advanced stages of building
an IMC - GMP approved extraction facility
for controlled production of high quality oils,
cannabinoids and active pharmaceutical
ingredients, aiming for EU - GMP
The facility is being built using the accumulated
expertise, know-how and experience of Solbar Group
Developing and enhancing extraction techniques and
stability testing in the company's lab, using state-of-
the-art equipment
Developing analytical and bio-analytical techniques for
the identification of single API's
Product development is led by the company's scientific
team, supported by a leading formulator
and accompanied by leading regulatory advisors
This activity has been acknowledged as innovative by
the Israeli Innovation Authority and granted financial
support
We do it right
Medical Cannabis
Extraction and
Processing
The construction of the facility is in accordance with
the Ministry of Health's initial permit requirements

14
Hadassah Medical-
A Strategic Partnership
for Distribution in Israel
and Commercial Activity
Expansion in International
Markets
Cannassure has signed an
agreement with Hadassah
Medical for marketing and selling
medical cannabis oil with the
Hadassah Medical brand name
in Israel and global markets
Cannassure is planning
to operate throughout
Hadassah Medical's
distribution channels,
as well as exploring more
collaborative mutual activity
We do it right

15
Cannassure intends to develop
and commercialize pharma-grade
products, for life threatening
diseases, in the field of oncological
gynecology, using selected, active
plant sourced cannabinoids
Cannassure is in the planning
phase of developing a new
product based on a combination
of cannabinoid active
ingredients together with an FDA
approved gynecological medical
device
A proprietary patent
application was filed
by Cannassure's expert
in pharmaceutical
intellectual property,
previously Intellectual
Property Team Manager
at Teva Pharmaceuticals
The new product development is led
by the company's scientific team,
assisted by a senior formulator
with regulatory guidance of several
leading regulatory firms
Cannassure is exploring options
for leveraging the collaboration
with Hadassah Hospital for the
development of the product
15
We do it right
Innovative Medical
Cannabis Products
Development

16
16
We do it right
Medical Cannabis
Innovative Center
Cannassure together with Cannika Holdings, a group
of experienced scientific experts, are establishing an
innovation center for early-stage medical cannabis
unique innovative products
1
The center will operate in Cannassure's campus,
utilizing state-of-the-art facilities, equipment,
and technologies
2
Entrepreneurs joining the innovation center will
benefit from a community of leading scientists,
researchers and business professionals
3
The innovation center activity is financed by
private investors
4

17
H2/20198.2018 6.2019 7.2019
17
and onwards
Extracting
medical
cannabis in
the analytical
laboratory
Completion of
extraction and
processing facility,
in accordance with
IMC - GMP regulatory
standards
Completion of
indoor grow facility
for breeding new
plant genetics
and developing
new strains, in
accordance with
IMC - GAP standards
Ready for production
and sale of IMC - GMP
approved medical
cannabis oil and
cannabis API's
We do it right
Next Steps, Key Milestones 2019

18
Infrastructure connected to reverse osmosis water supply, natural gas and cost-reduced
electricity, allowing competitive, efficient and clean production environment
18
Founded on the know-how, experience and expertise of Solbar Group, a leader in the
food and agriculture industry and benefits from its infrastructure and financial support
Rapidly establishing an indoor growing facility in a controlled environment, for premium
quality and consistent cannabis flowers
Rapidly establishing a highly professional complete value chain in the medical
cannabis industry
Equipped to meet and swiftly adjust to changing requirements, based on Solbar Group
know-how and experience
The global medical
cannabis industry
is undergoing
rapid growth and
development
Cannassure has clear
competitive advantages
to become a significant
entity in the medical
cannabis industry
Summary
We do it right
Strategic agreement with Hadassah Medical for collaboration and marketing of medical
cannabis products worldwide
Establishing a technological incubator for medical cannabis innovation within the
company's campus
Cannassure's Competitive Advantages
Skilled highly experienced management team in international business, bio-tech,
nutraceutical and food industries

19
Thank You
February 2019 | Ran Amir Ran.amir@cannassure.life www.linkedin.com/company/cannassure
TASE:

Cannassure Therapeutics Investors Deck

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Cannassure Therapeutics Investors Deck

Similar to Cannassure Therapeutics Investors Deck (20)

Recently uploaded

Recently uploaded (20)

Cannassure Therapeutics Investors Deck